Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many mechanistic/biology claims are not supported by the supplied label excerpts, while several core label elements (single-dose IV infusion and pediatric SMA indication with SMN1 bi-allelic mutations) align. Monitoring of liver function is supported, but broader statements about vector circulation/cell entry and immune-related reactions are not verifiable from the provided text.
Category Scores
Accurate Statements
Zolgensma is designed for spinal muscular atrophy (SMA).
Section 1: indicated for pediatric patients < 2 years of age with SMA with bi-allelic SMN1 mutations.
Zolgensma is a one-time gene therapy.
Section 2: For single-dose intravenous infusion only.
After an IV infusion, the AAV9 vector circulates in the body.
Clinicians monitor liver enzyme elevations associated with the therapy.
Section 2.3: Liver function monitoring includes AST, ALT, total bilirubin, and other coagulation parameters; monitoring schedule provided.
Clinicians monitor immune-related reactions associated with the therapy.
Unsupported Statements
Zolgensma is built on an engineered AAV9 (adeno-associated virus) vector.
The supplied excerpts do not state the vector is engineered or specify engineered AAV9 construction details beyond AAV context.
Zolgensma delivers a functional copy of the SMN1 gene to patients’ cells.
The supplied excerpts do not describe delivery of a functional SMN1 gene to cells.
After delivery of the SMN1 gene, the body can produce the survival motor neuron (SMN) protein that is missing or too low in spinal muscular atrophy (SMA).
The supplied excerpts do not describe the mechanistic production of SMN protein after delivery.
In SMA, motor neurons degenerate because SMN protein levels are insufficient.
The supplied excerpts do not include disease mechanism statements about motor neuron degeneration due to insufficient SMN.
In most SMA types, loss or mutation of SMN1 reduces SMN production.
Not present in the supplied excerpts.
In most SMA types, patients rely on limited SMN2 copies that do not generate enough SMN protein.
Not present in the supplied excerpts.
Zolgensma provides a working SMN1 gene product to raise SMN protein levels in the body.
Not present in the supplied excerpts.
After an IV infusion, the AAV9 vector circulates in the body.
Not present in the supplied excerpts.
After an IV infusion, the AAV9 vector enters cells (especially motor neuron-relevant cells).
Not present in the supplied excerpts.
Inside cells, the delivered SMN1 genetic instructions are used to produce SMN protein.
Not present in the supplied excerpts.
The produced SMN protein helps support motor neuron survival and function.
Not present in the supplied excerpts.
Gene delivery and increased SMN protein production do not mean symptoms improve instantly.
Not present in the supplied excerpts.
Functional improvement in SMA typically depends on how much motor neuron function remains at the time of treatment.
Not present in the supplied excerpts.
Functional improvement in SMA typically depends on how effectively SMN levels rise in relevant tissues.
Not present in the supplied excerpts.
Clinicians monitor safety issues associated with the therapy’s viral vector and gene-expression effects.
Not present in the supplied excerpts (only specific monitoring elements in Section 2.3 are shown).
Liver enzyme elevations are described as a hepatotoxicity risk for the therapy.
While liver function monitoring is described, the supplied excerpts do not explicitly characterize liver enzyme elevations as a hepatotoxicity risk.
Clinicians monitor immune-related reactions associated with the therapy.
The supplied excerpts do not provide an immune-related reaction monitoring statement.
Contradictions
Important Omissions
The labeled indication is restricted to pediatric patients less than 2 years of age with SMA with bi-allelic SMN1 mutations (and limitations of use: no evaluation for repeat administration; not evaluated in advanced SMA such as complete paralysis or permanent ventilator dependence).
Importance:
Moderate
Specific monitoring beyond liver function (e.g., platelet counts weekly/monthly schedule) included in Section 2.3 was not addressed in the AI claims list.
Importance:
Moderate
Baseline anti-AAV9 antibody testing and potential retesting criteria (>1:50) were included in Section 2.3 but were not reflected in the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are mechanistic and not supported by the supplied label excerpts; while these are unlikely to be directly actionable from the provided information, missing labeled limitations (age <2 years, bi-allelic SMN1 mutations, and limitations of use) could lead to inaccurate labeling of the intended population.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many mechanistic/vector-routing statements and immune monitoring claims are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Constrain claims to what is explicitly supported by the provided label text: (1) labeled indication details (pediatric <2 years; SMA with bi-allelic SMN1 mutations) and listed limitations of use; (2) dosing instruction (single-dose IV only); (3) monitoring elements shown in Section 2.3 (baseline anti-AAV9 testing, liver function monitoring schedule and parameters, platelet count schedule).